Company Filing History:
Years Active: 2014
Title: Philippe Marc Louis Alard: Innovator in Anti-Beta-Amyloid Antibodies
Introduction
Philippe Marc Louis Alard is a notable inventor based in Gent, Belgium. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on addressing critical health issues, including Alzheimer's disease.
Latest Patents
Alard holds a patent for "Humanized anti-beta-amyloid antibodies." This patent involves antigen binding proteins that specifically target the beta-amyloid peptide, especially the human variant. The invention outlines methods for treating diseases characterized by elevated beta-amyloid levels, including Alzheimer's disease and other disorders affecting the eye or optic nerve. The patent also covers pharmaceutical compositions and methods of manufacture related to these antigen binding proteins.
Career Highlights
Philippe Marc Louis Alard is associated with Glaxo Group Limited, where he has been instrumental in advancing research and development in therapeutic solutions. His innovative approach has led to the creation of valuable medical treatments that aim to improve patient outcomes.
Collaborations
Alard has collaborated with notable colleagues, including Ian Richard Catchpole and Jonathan Henry Ellis. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Philippe Marc Louis Alard's contributions to the field of biotechnology, particularly through his patent on anti-beta-amyloid antibodies, highlight his role as a key innovator in addressing significant health challenges. His work continues to pave the way for advancements in treatments for diseases like Alzheimer's.